Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications by Katholi, Richard E. & Couri, Daniel M.
SAGE-Hindawi Access to Research
International Journal of Hypertension
Volume 2011, Article ID 495349, 10 pages
doi:10.4061/2011/495349
Review Article
Left Ventricular Hypertrophy:Major Risk Factor in Patients with
Hypertension:Update and Practical Clinical Applications
RichardE.Katholi andDanielM.Couri
Prairie Cardiovascular Consultants, Ltd., 619 E. Mason Street, Ste. 4P57, Springﬁeld, IL 62701, USA
Correspondence should be addressed to Richard E. Katholi, rkatholi@prairieheart.com
Received 15 February 2011; Accepted 19 April 2011
Academic Editor: Amgad N. Makaryus
Copyright © 2011 R. E. Katholi and D. M. Couri. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Left ventricular hypertrophy is a maladaptive response to chronic pressure overload and an important risk factor for atrial
ﬁbrillation, diastolic heart failure, systolic heart failure, and sudden death in patients with hypertension. Since not all patients
with hypertension develop left ventricular hypertrophy, there are clinical ﬁndings that should be kept in mind that may alert the
physiciantothepresenceofleftventricularhypertrophysoamoredeﬁnitiveevaluationcanbeperformedusinganechocardiogram
or cardiovascular magnetic resonance. Controlling arterial pressure, sodium restriction, and weight loss independently facilitate
the regression of left ventricular hypertrophy. Choice of antihypertensive agents may be important when treating a patient with
hypertensive left ventricular hypertrophy. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers followed
by calcium channel antagonists most rapidly facilitate the regression of left ventricular hypertrophy. With the regression of left
ventricular hypertrophy, diastolic function and coronary ﬂow reserve usually improve, and cardiovascular risk decreases.
1.Introduction
While there are many proven beneﬁts for the successful long-
term treatment of hypertension including decreasing risk of
stroke, renal failure, and myocardial infarction, an increas-
ingly important area of hypertension treatment is to identify
left ventricular hypertrophy and prescribe a combination of
therapies which facilitates regression to improve patients’
symptoms and prognosis. Left ventricular hypertrophy is
both a major maladaptive response to chronic pressure
overload and an important risk factor in patients with
hypertension. The development of left ventricular hypertro-
phy is highly correlated with systolic hypertension. In the
Framingham Heart Study, even borderline isolated systolic
hypertension at an elderly age was associated with increased
left ventricular wall thickness and impaired diastolic ﬁlling
[1]. Complications of left ventricular hypertrophy include
atrial ﬁbrillation, diastolic heart failure, systolic heart failure,
and sudden death. Both earlier recognition and improved
understanding of cardiac hypertrophy may lead to more
eﬀective therapeutic strategies for this cardiovascular risk
factor. This paper will focus on concentric left ventricular
hypertrophy and discuss diﬀerential diagnosis, which tech-
niques are available to identify left ventricular hypertrophy,
and therapies to decrease patients’ risks and to facilitate
regression to improve symptoms and prognosis. This paper
will also discuss novel therapies in development which may
have a signiﬁcant impact on this high-risk problem in the
future.
2. FactorsPromoting Left
VentricularHypertrophy
It is now appreciated that left ventricular hypertrophy is
mediated not only by the mechanical stress of pressure
overload, but also by various neurohormonal substances
that independently exert trophic eﬀects on myocytes and
nonmyocytes in the heart [2]. As shown in Table 1,t r o p h i c
factors include angiotensin II, aldosterone, norepinephrine,
and insulin which directly promote myocyte hypertrophy
and matrix deposition independent of their eﬀects on
systemic arterial pressure [3, 4]. These trophins stimulate
the production of a series of cytokines and growth factors2 International Journal of Hypertension
Table 1: Factors promoting left ventricular hypertrophy.
Hypertension
Neurohumoral factors (growth stimulation)
Angiotensin II
Aldosterone
Norepinephrine
Insulin and other growth factors
Genetic inﬂuences
including transforming growth factor beta, ﬁbroblast growth
factor, and insulin growth factor that directly stimulate
cardiac protein synthesis and hypertrophy. While elevated
systemic arterial pressure plays a role in the pathogenesis
of left ventricular hypertrophy, the extent of cardiac growth
and response to increased pressure loading is not uniform
among patients suggesting genetic mechanisms in cardiac
hypertrophy [5]. Thus, patients with moderate arterial
h y p e r t e n s i o np r e s e n tw i t haw i d er a n g eo fl e f tv e n t r i c u l a r
mass, ranging from normal heart to severe hypertrophy. In
addition, the remodeling of the left ventricle may take a
concentric or an eccentric form independent of the extent
of blood pressure elevation.
3. ClinicalSuspicion for Left
VentricularHypertrophy
The primary care physician encounters many patients with
hypertension. An electrocardiogram (but not an echocardio-
gram) is suggested in the initial evaluation of patients with
hypertension to detect arrhythmias, evidence of ischemic
heart disease, and/or left ventricular hypertrophy [6]. Since
not all patients with hypertension develop left ventricular
hypertrophy, there are clinical ﬁndings that should be kept
in mind that may alert the physician to the presence of left
ventricular hypertrophy so a more deﬁnitive evaluation can
be performed. The detection of left ventricular hypertrophy
is important because these patients’ risk of cardiovascular
morbidity and mortality is two-to-four-fold increased com-
pared to patients with normal left ventricular mass [7, 8].
Although echocardiography is a more sensitive tool for
identifying left ventricular hypertrophy, cost has kept it from
becomingpartoftheroutineevaluationofanuncomplicated
asymptomatic patient with hypertension. If an S4 gallop
is noted on physical examination, one should consider
early diastolic dysfunction and possible left ventricular
hypertrophy. Abnormal electrocardiogram ﬁndings include
left atrial enlargement, prolongation of the QT interval, and
left ventricular hypertrophy. If graded exercise testing is
done, it is often noticed that patients with left ventricular
hypertrophy demonstrate a hyperadrenergic response with
increasesinheartrateto150beatsperminutewithintheﬁrst
minute and excessive elevations of systolic blood pressure
of greater than 200mmHg. A hyperadrenergic response of
heart rate and blood pressure explains the patient’s dyspnea
on exertion and is also thought to reﬂect the presence of left
ventricular hypertrophy [9].
There are a number of distinguishing clinical features
which appear to identify speciﬁc subgroups of hyperten-
sive patients who have left ventricular hypertrophy. Of
patients with left ventricular hypertrophy presenting with
anginal equivalent symptoms, 85% of these patients have
been found to be women with a mean age of 63 years,
and 83% had exogenous obesity [10]. Thus, the typical
hypertensive patient that one should be suspicious of
havingleftventricularhypertrophyisanoverweight,middle-
aged, postmenopausal female who presents to a physician
with a history of exertional chest pain that is typical of
angina pectoris. The patient will often give a history of
hypertension, but, typically, it is not severe. In addition, the
patient commonly has no smoking history, is not glucose
intolerant, and has a borderline dyslipidemia. These ﬁndings
superimposedonapositivegradedexercisetestaresuggestive
of hypertensive heart disease in women. That they developed
concentric left ventricular hypertrophy disproportionate to
the arterial pressure and had associated obesity suggests a
genetic basis for this problem. Left ventricular hypertrophy
in women is now considered to be a strong cardiovascular
risk factor independent of blood pressure [11, 12]. Studies
reveal an increased incidence in atrial ﬁbrillation and
sudden death in women with left ventricular hypertrophy. In
addition, hypertensive heart disease is a common cause of
congestive heart failure in women. One can only speculate
why postmenopausal women with mild-to-moderate left
ventricular hypertrophy have more angina than men with
a similar degree of left ventricular hypertrophy. Speculation
includes that women have smaller coronary arteries and/or
greater perception of pain because of the loss of analgesic
eﬀects of estrogen and/or because loss of estrogen results
in less endothelial nitric oxide production in the coronary
vascular tree [13, 14].
Metabolic syndrome has been associated with an
increased left ventricular mass in recent reports. Even after
controlling for age, sex, and 24-hour systolic blood pressure,
subjects with metabolic syndrome have signiﬁcantly greater
left ventricular mass [15]. The lack of association between
left ventricular mass and blood pressure in patients with
metabolic syndrome suggests other factors such as insulin
resistance and hyperinsulinemia, sodium retention, sympa-
thetic activation, and adipose tissue peptides such as leptin
may be responsible. Accordingly, the primary care physician
should be aware of the impact of metabolic syndrome on
left ventricular mass in overweight and obese hypertensive
patients and screen this high-risk group for this cardiovascu-
lar complication. Other patient types that should be kept in
mind so that the primary care physician is alert to pursue a
workup for left ventricular hypertrophy is the obese patient
who should be screened for sleep apnea. Patients who have
sustained the elevation of blood pressure throughout the
night and do not have the normal nocturnal fall of arterial
pressure are at increased risk of developing left ventricular
hypertrophy [16]. African American and Caribbean and
Mexican-origin Hispanic patients with hypertension also
have a higher incidence of left ventricular hypertrophy and,
thus, the clinician should have a higher index of suspicion
and consider screening for left ventricular hypertrophy [17].International Journal of Hypertension 3
Most studies suggest that African American and Caribbean
andMexican-originHispanicpatientshavenotonlyagreater
left ventricular wall thickness, but also a greater left ventric-
ular mass, even with equivalent blood pressures than white
patients. The most diﬃcult patient to identify is the patient
with“masked”hypertension.Thissubsetofpatientsreactsin
an opposite way to patients with “white coat” hypertension
[18]. Instead of the patient’s blood pressure being elevated
when sitting in a doctor’s oﬃce, the blood pressures are
normal. However, when these patients are performing daily
activities, including exercise, they have an excessive elevation
in systolic blood pressure. Thus, throughout the day, their
heart has increased afterload which acts as a stimulus for
hypertrophy when they are undergoing normal activities.
Arteriolarthickeningonfunduscopicexamination,S4gallop,
abnormal EKG, or exercise testing may suggest that the
patient has “masked” hypertension, and ambulatory blood
pressure monitoring can conﬁrm this subset of hypertensive
patients.
Left ventricular hypertrophy should also be suspected in
hypertensive patients found to have unilateral renal artery
stenosis [19, 20]. There is evidence that the activation of the
renin-angiotensin-aldosterone system may contribute to the
development of left ventricular hypertrophy independent on
eﬀects of blood pressure. Left ventricular hypertrophy has
been shown to be three times more prevalent in patients
with functionally signiﬁcant unilateral renal artery stenosis
compared to patients with essential hypertension.
There also appears to be an increase in left ven-
tricular mass beyond the amount needed to compensate
the blood pressure-related hemodynamic load in patients
with primary aldosteronism [21]. Because hypertension and
obesity increase with age, the prevalence of left ventricular
hypertrophy may be 50 percent in patients over 65 years
of age [22]. Finally, there is a high prevalence of left
ventricular hypertrophy in patients with renal insuﬃciency.
Left ventricular hypertrophy is present in approximately 70
percent of patients at the initiation of dialysis [23].
4. DifferentialDiagnosisof Left Ventricular
Hypertrophy andImagingApproaches to
DifferentiatePhysiologic from
Pathologic Hypertrophy
T h ea d u l tm y o c yt ei sat e rm i n a ll yd i ﬀerentiated cell that does
not divide in response to stress [3, 4]. Thus, the myocyte
adaptstoapressureoverloadbythereplicationofsarcomeres
and by changes in enzyme isoforms which regulate contrac-
tile function and ion transport, resulting in a more eﬃcient,
energy-conserving contraction. Hypertrophy secondary to
exercise or hyperthyroidism appears appropriate in regard
to remodeling of the left ventricular with relative dilatation
which represents advantageous use of Frank-Starling forces
to achieve greater eﬃciency of energy use and because coro-
nary ﬂow reserve is appropriate for the degree of myocardial
growth [24, 25]. In contrast, left ventricular hypertrophy
secondary to essential hypertension is pathological with
stimulus to growth also activating ﬁbroblasts leading to an
interstitial ﬁbrosis which is another feature of the structural
remodeling of the myocardium found in hypertensive heart
disease. Thus, in left ventricular hypertrophy secondary
to essential hypertension, left ventricular chamber size is
smaller with elevated diastolic ﬁlling resulting in a blunting
of the heart’s ability to eﬃciently use energy, and coronary
ﬂow reserve remains below that expected for the degree of
hypertrophy [26].
If a patient has hypertension and also participates in a
regularintensive aerobicactivity suchasjogging orbicycling,
diﬀerentiating physiologic from pathologic increase in left
ventricularmassisanimportantandchallengingassessment.
Chronic aerobic exercising can cause electrocardiographic
changes that can mimic pathological conditions and highly
conditioned individuals can harbor suspected cardiovascular
diseasedespitetheabsenceofcardiacsymptoms[27].Distin-
guishing between physiological athletic heart and pathologic
left ventricular hypertrophy has important implications for
trained athletes or individuals with vigorous avocations.
Pathologic left ventricular hypertrophy may be the basis for
disqualiﬁcation from intense competitive sport activities to
reduce the risk of sudden death [28]. Alternatively, over
diagnosis can lead to unnecessary restrictions, depriving
athletes and/or exercise participants of the monetary and/or
psychological beneﬁts of vigorous aerobic sports. For the
clinician faced with deciding whether this is structural
heart disease or athlete’s heart, an echocardiogram is very
helpful [29]. Several considerations are important: (1) Left
ventricular systolic and diastolic function is normal in
the athlete. Remember, ejection fraction in a left ventricle
with physiologic diastolic dilatation (LV cavity greater than
55mm) and a slow heart rate will be in the low normal
rangeof50–55percent.(2)Theleftventricularwallthickness
is usually less than but not greater than 12mm. (3) The
individual will give a history of training and competing
in sports combining aerobic endurance and strength. (4)
The individual will have a slow resting heart rate due to
training-induced increased parasympathetic activity on the
sinus node [27]. If the individual has a left ventricular end
diastolic dimension of less than 45mm and/or left ventric-
ular wall thickness of greater than 15mm, pathologic left
ventricular hypertrophy should be suspected [27, 30]. Tests
such as Doppler echocardiogram or cardiovascular magnetic
resonance become important additional implements in the
diﬀerential diagnosis in some patients. For example, about
two percent of highly trained adult male athletes show
increased left ventricular wall thickness of 13–15mm which
deﬁne a “gray zone” where extreme expressions of athlete
heart and mild pathologic left ventricular hypertrophy
overlap[31].Suchdiagnosticambiguitycanoftenberesolved
with noninvasive testing such as the assessment of diastolic
ﬁlling with Doppler echocardiography.
Due to technical advances, cardiovascular magnetic
resonance is now ﬁrmly established in research and clin-
ical cardiovascular medicine. While echocardiography is a
faster and more portable modality, cardiovascular magnetic
resonance typically provides superior reproducible image
quality. Both echocardiography and magnetic resonance
are nonionizing technologies which in the modern climate4 International Journal of Hypertension
of safety priority are favored over X-ray and gamma-ray
modalities in the evaluation and long-term management of
patients with left ventricular hypertrophy [32, 33]. Changes
in left ventricular mass can indicate disease progression
or regression in hypertensive heart disease. Cardiovascular
magnetic resonance is superior to echocardiology because
of excellent reproducibility and because echocardiographic
methods are dependent on symmetry on left ventricular
shape [34]. Because of cost, echocardiology is more com-
monly used in clinical assessment of hypertensive patients.
However, measuring changes in left ventricular mass using
cardiovascular magnetic resonance has become a precise
useful research tool when testing the beneﬁt of pharmaco-
logic treatment of hypertensive left ventricular hypertrophy
[35]. While not the focus of this article, patients may
present with hypertension, left ventricular hypertrophy on
electrocardiogram, and increased left ventricular mass who
have hypertrophic cardiomyopathy rather than hypertensive
heart disease. Cardiovascular magnetic resonance imaging
is useful to distinguish hypertensive and hypertrophic car-
diomyopathy [36]. Recent studies indicate the presence of
distinctive hypertrophic phenotypes detectable by means
of multiparametric magnetic resonance imaging. In hyper-
tension, impaired deformation follows the distribution of
left ventricular wall stress. In contrast, hypertrophic car-
diomyopathy is characterized by reduced global and regional
deformation in association with ﬁbrosis.
5. Nonpharmacologic Strategies for Prevention
and Regression of Pathologic Hypertrophy
Eﬀective, long-term antihypertensive therapy focused on
the regression of left ventricular hypertrophy is indicated
in these patients and requires speciﬁc nonpharmacologic
and pharmacologic consideration and treatment. With the
regression of left ventricular hypertrophy, diastolic function
and coronary ﬂow reserve usually improve, and risk of
atrial ﬁbrillation, congestive heart failure, and cardiovascular
mortality decreases [37–42]. Goal of therapy is an arterial
blood pressure of 130/80mm Hg or better. Left ventricular
hypertrophy regression necessitates eﬀective arterial blood
pressure lowering 24 hours a day. In patients who appear
to be at goal but fail to regress, 24-hour blood pressure
ambulatory monitoring can be used to determine whether
arterial pressure is, in fact, eﬀectively controlled.
In addition to controlling arterial pressure, sodium
restriction and weight loss independently facilitate the
regression of left ventricular hypertrophy [43]. If the patient
even loses 10 pounds, it enhances the antihypertensive eﬀect
of medications, and associated weight loss speeds up the
potential for regression. Weight loss facilitating the regres-
sion of left ventricular hypertrophy has been accomplished
through moderate calorie restriction in combination with
regular low resistance exercise, such as walking 30 minutes
ad a y[ 44]. Other interventions for successful treatment of
hypertension to allow for the regression of left ventricular
hypertrophy include minimizing use of nonsteroidal, anti-
inﬂammatory medications which inhibit synthesis of renal
prostaglandin resulting in renal vasoconstriction, salt, and
water retention and more diﬃcult-to-control high blood
pressure [24]. It is important to recognize excessive alcohol
intake and limit it as a correctable factor for treatment of
hypertension. It is also important to recognize sleep apnea
and treat this condition, for sleep apnea can contribute to
and cause hypertension, and treatment of sleep apnea has
been shown to facilitate the regression of left ventricular
hypertrophy [45].
6. Pharmacologic Strategies for Prevention and
Regression of Pathologic Hypertrophy
Choice of antihypertensive agents may be important when
treating a patient with hypertension and left ventricular
hypertrophy.Theclassesofantihypertensiveagentsthatmost
rapidly facilitate the regression of left ventricular hyper-
trophy are the angiotensin-converting enzyme inhibitors
and the angiotensin II receptor blockers followed by cal-
cium channel antagonists [46–49]. Angiotensin-converting
enzyme inhibitors and angiotensin II receptor blockers
are particularly eﬀective because angiotensin II has been
found to have a direct tropic eﬀect of the pathogenesis
of left ventricular hypertrophy [42, 50, 51]. Decrease in
left ventricular mass may occur in as little as three to six
months.Thedirectrenininhibitoraliskirenisalsoeﬀectivein
facilitating the regression of left ventricular mass [52]. Thus
far, the potential beneﬁt of combining either an angiotensin
II receptor blocker or an angiotensin-converting enzyme
inhibitor with a direct renin inhibitor is under investigation.
The initial trial combining an angiotensin II receptor blocker
with a direct renin inhibitor did not show an additive beneﬁt
on the regression of left ventricular hypertrophy [52].
Angiotensin-converting enzyme inhibitors also appear to
beneﬁt patients with left ventricular hypertrophy because
they improve coronary endothelial function by bradykinin-
mediated release of nitric oxide and decrease myocardial
oxygen consumption by nitric oxide inhibition of mito-
chondrial respiration [53]. When initiating angiotensin-
converting enzyme inhibitors in patients, it is important
to warn the patients of the life-threatening side eﬀect
of angioedema. This idiosyncratic side eﬀect occurs in a
small number of patients. When on angiotensin-converting
enzyme therapy, patients should be warned if they start
developing shortness of breath or swelling of the throat
and tongue, they should stop the angiotensin-converting
enzyme inhibitor and immediately go to the emergency
room since this is a potentially life-threatening side eﬀect.
When starting an angiotensin-converting enzyme inhibitor,
angiotensin II receptor blocker, or direct renin inhibitor, it
is also important to screen for a change in renal function.
A small number of patients who have unrecognized renal
artery stenosis, whether it be large vessel or small vessel
disease, will have a decrease in renal perfusion pressure
because of the loss of intrarenal angiotensin II maintenance
of renal perfusion balance between aﬀerent and eﬀerent
arterioles. In these patients, serum creatinine will increase
due to decreased glomerular ﬁltration rate. This is easilyInternational Journal of Hypertension 5
detected by measuring a baseline serum creatinine and then
checking serum creatinine again within a week. If serum
creatinine increases by greater than 0.3mg/dL from baseline,
the angiotensin-converting enzyme inhibitor, angiotensin
II receptor blocker, or direct renin inhibitor should be
discontinued, and this reversible decrease in glomerular
ﬁltration rate will correct itself.
Thus far, the angiotensin-converting enzyme inhibitor
and the angiotensin II receptor blocker trials suggest treat-
ing risk factors beyond high blood pressure and should,
therefore, be used in hypertensive African American patients
with left ventricular hypertrophy independent of blood
pressure-lowering eﬀects [54]. However, blood pressure
control is paramount to reduce cardiovascular morbidity
and mortality in these high-risk patients. Thus, other
classes of antihypertensive agents such as diuretics and
calcium channel blockers are usually needed in combina-
tion with an angiotensin-converting enzyme inhibitor or
an angiotensin II receptor blocker to achieve goal blood
pressure. Angiotensin-converting enzyme inhibitor cough
has been found to be more common in African Americans
than in whites. In contrast, angiotensin II receptor blockers
have consistently been found to have a side-eﬀect proﬁle
not greater than that of placebo. Therefore, an angiotensin
II receptor blocker may become an important addition to
the antihypertensive regimen of African Americans with left
ventricular hypertrophy.
Besides facilitating the regression of left ventricular
hypertrophy, calcium channel antagonists improve coronary
blood ﬂow in patients with left ventricular hypertrophy
[55, 56]. Longer-acting calcium channel antagonists are
safe and appropriate for treatment of hypertensive patients
with left ventricular hypertrophy. Choice of calcium channel
antagonists should be dictated by the patient’s resting
heart rate and response to exercise. If a patient has a
hyperadrenergicresponsetoexercise,verapamil,ordiltiazem
are appropriate choices for symptomatic relief because
these calcium channel antagonists attenuate both the heart
rate and blood pressure response to exercise. In contrast,
traditional beta-adrenergic receptor blocking agents only
attenuate the heart rate response to exercise and actually can
(due to unopposed alpha constriction) cause an accentuated
systolic blood pressure elevation during exercise. In contrast,
carvedilol and labetalol which have alpha-blocking proper-
ties attenuate both heart rate and exercise response similar to
verapamil and diltiazem, thus, providing symptomatic relief
of symptoms of dyspnea or angina and also these agents
facilitate a slower heart rate to allow for better diastolic
ﬁllingoftheventricle.Inolderpatientswhohaveconduction
system disease and slower heart rates, dihydropyridines are
beneﬁcial, and the dihydropyridine which best seems to
facilitate the regression of left ventricular hypertrophy is
amlodipine [49].
Several lines of evidence suggest that combining an
angiotensin-converting enzyme inhibitor or an angiotensin
II receptor blocker with amlodipine may have additive
eﬀects, not only in blood pressure regulation, but to
facilitate the regression of left ventricular hypertrophy and
also decrease mortality [49]. Peripheral alpha-adrenergic
blocking agents, thiazide-type diuretics, and even traditional
beta-adrenergic receptor blocking agents also allow for left
ventricular hypertrophy regression over time [24, 46]. Cen-
trally acting alpha agonists have not been carefully studied
for their eﬀects on left ventricular hypertrophy regression.
Directvasodilators,suchasminoxidilandhydralazine,which
further stimulate renin-angiotensin-aldosterone system and
sympathetic nervous system activity, although eﬀective in
controlling blood pressure, are ineﬀective with regard to the
regression of left ventricular hypertrophy [24].
Current treatment recommendations for hypertensive
patients with left ventricular hypertrophy are based on blood
pressure lowering and do not speciﬁcally favor selection
o fap a r t i c u l a rb e t a - b l o c k e ro v e ra n o t h e re x c e p tt oa v o i d
beta-blockerswithintrinsicsympathomimeticactivitywhich
may increase left ventricular mass and increase the risk
of sudden death [24]. However, recent trials emphasize
the class heterogeneity that exists for beta-blockers and
provide a strong basis for preferred use of carvedilol in
these high-risk patients. Carvedilol is a unique molecule that
combines the properties of a nonspeciﬁc beta-blocker and
a speciﬁc alpha-1-blocker in a ratio of 2:3. Carvedilol also
possesses antioxidant properties. Several studies have shown
that carvedilol signiﬁcantly reduces left ventricular mass and
myocardial ﬁbrosis in both animals and humans [57, 58].
In patients with hypertensive left ventricular hypertrophy
and decreased coronary ﬂow reserve, carvedilol treatment
compared to metoprolol treatment over six months showed
a greater decrease in left ventricular mass index and a greater
recovery in coronary ﬂow reserve [59].
Patients with hypertensive left ventricular hypertrophy
are at an increased risk of progressing to left ventricular
systolic dysfunction heart failure [60]. Studies have shown
that angiotensin-converting enzyme inhibitors delay the
development of congestive heart failure [51]. Animal studies
indicate a role of oxidate stress causing myocyte apoptosis
in the transition of hypertrophy to systolic heart failure
[61]. Carvedilol with its complete sympathetic blockade
and antioxidant properties may be an appropriate choice
for the prevention of heart failure in these patients. This
concept is reinforced by the beneﬁcial eﬀects of carvedilol
for the reduction in morbidity and mortality in patients
after myocardial infarction and with systolic congestive heart
failure [62, 63].
Left ventricular hypertrophy and dyslipidemia are strong
and independent predictors of cardiovascular morbidity and
mortality with hypertension. Traditional beta-blockers have
been shown to worsen insulin resistance, facilitate weight
gain, and increase triglycerides [64]. Carvedilol in hyperten-
sive patients with diabetes has been found to have a neutral
eﬀect on insulin resistance, weight, and triglycerides [64].
This favorable metabolic proﬁle also suggests that carvedilol
is a better choice compared to traditional beta-blockers in
these high-risk patients. Similarly, other antihypertensive
agents indicated for treatment of hypertensive patients
with left ventricular hypertrophy, including angiotensin-
converting enzyme inhibitors, angiotensin II receptor block-
ers, calcium channel blockers, and central sympatholytic6 International Journal of Hypertension
agents are lipid neutral. In contrast, peripheral alpha-
adrenergicblockingagentshavebeenshowntoincreaseHDL
c h o l e s t e r o la sw e l la sd e c r e a s et o t a la n dL D Lc h o l e s t e r o l[ 24].
T h i a z i d e - t y p ed i u r e t i c sa n dt os o m ed e g r e el o o pd i u r e t i c s
increase total cholesterol. The thiazide-type diuretics at
dosages of 6.25 or 12.5mg daily have only small eﬀects on
total cholesterol. Of note, indapamide is lipid neutral and
thus has a somewhat diﬀerent pharmacologic eﬀect on lipids
compared to the other diuretics [24].
Diuretics in low dosage enhance the antihypertensive
eﬀects of most antihypertensive medications. Older patients
with stiﬀ vessels usually have a volume-sensitive hyperten-
sion, and a low dose of a thiazide-type diuretic can be very
eﬀective therapy. However, when a patient’s creatinine clear-
ance is less than 50mL/min, most thiazide-type diuretics are
less eﬀective for volume control and antihypertensive ther-
apy. In these patients, alternatives would be chlorthalidone
or indapamide which are eﬀective despite decreased renal
function. Loop diuretics can also be used in patients with
decreased renal function, but to achieve antihypertensive
responses, a loop diuretic, such as furosemide has to be
given twice daily. In patients with resistant hypertension,
thiazide-type diuretic is very important component of the
pharmacologic antihypertensive therapy. In the patient with
hypertension and left ventricular hypertrophy requiring
diuretic therapy, it is important to keep the potassium
between 4 and 5mEq/L and magnesium at 2mEq/L or
greater to decrease the risk of ventricular arrhythmias [65,
66]. When extracellular potassium is less than 4mEq/L or
greater than 5mEq/L, atrial and ventricular cells are depolar-
ized and more prone to atrial and ventricular arrhythmias.
Extracellular hypomagnesemia has also been shown to
depolarize atrial and ventricular muscle cells making them
more prone to atrial and ventricular arrhythmias [67].
Serum potassium and magnesium levels reﬂect extracellular
potassium and magnesium and, thus, are a sensitive guide
to replacement therapy. Left ventricular hypertrophy is a
substrate for ventricular arrhythmias because left ventricular
hypertrophy prolongs the QT interval. Left ventricular
hypertrophy in the setting of low potassium and/or low
magnesium increases the risk of ventricular arrhythmias and
even sudden death.
Evidenceindicatesthatthealdosteronereceptorblockers,
spironolactone, or eplerenone are eﬀective in facilitating
the regression of left ventricular hypertrophy [68]. High
aldosterone levels in experimental animals have been found
to increase the ﬁbrosis in the cardiac interstitial space, and
ﬁbrosis is part of the process of pathologic left ventricular
hypertrophy. In experimental animals with left ventricu-
lar hypertrophy, the use of spironolactone or eplerenone
decreases the development of ﬁbrosis in pathologic left
ventricular hypertrophy and even seems to facilitate its
regression. If a thiazide-type diuretic is required, con-
comitant use of spironolactone or eplerenone is useful in
conserving potassium and magnesium as well as facilitating
the regression of left ventricular hypertrophy. Of note, beta-
adrenergic receptor blocking agents, angiotensin-converting
enzyme inhibitors, and angiotensin II receptor blockers tend
to normalize the QT interval in patients with left ventricular
hypertrophy. Using the above pharmacologic agents, it is
important to not only achieve goal of blood pressure
of 130/80mmHg or better, but also to attenuate blood
pressure variability. Choosing antihypertensive agents with
longer half lives has a smoothing eﬀect on blood pressure
and may explain the mortality beneﬁts of longer-acting
angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, amlodipine, and chlorthalidone [69].
Angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, and dihydropyridine calcium-channel
blockers may also be eﬀective in preventing or facilitating
the regression of left ventricular hypertrophy because these
medications reduce reﬂected pressure waves thus lowering
central (aortic) blood pressure [70]. A 3-4mmHg lower
central (aortic) blood pressure over time should result in less
left ventricular hypertrophy.
7.FutureNovelApproachestothe
Treatment of Left VentricularHypertrophyin
Patients with Hypertension
A future potential therapeutic concept for the treatment of
hypertension and to facilitate the regression of left ventricu-
lar hypertrophy is inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A reductase (statins). Statins have been shown
to facilitate the regression of left ventricular hypertrophy in
various animal models of pathological myocardial growth
[71, 72]. In addition to the reduction of left ventricular
mass, statins have been shown to reduce myocardial ﬁbrosis,
increase capillary density network, and attenuate electrical
instability of the hypertrophied heart. Most importantly,
statins improved systolic and diastolic left ventricular func-
tion and even decreased mortality. The mechanisms of these
beneﬁcial eﬀects are still under investigation. As statins lower
cholesterol,endothelialfunctionimprovesandsystolicblood
decreases by 2–4mmHg. The inhibition of hypertrophic
growth by statins is only partly achieved by the reduction
of hemodynamic overload. Direct mechanisms such as the
inhibition of neurohumoral activation in the myocardial
tissue, attenuated production of growth factors and markers
of inﬂammation, and the reduction of oxidative stress also
seem to participate. Thus, statins appear to exert biological
eﬀects other than their cholesterol-lowering actions. The
additional protective eﬀect of statins is associated with the
inhibition of expression and activation of small guanosin
triphosphate-binding proteins such as Ras and Rho which
control the intensity of oxidative stress, the production and
availability of nitric oxide, and the expression of genes
involved in myocardial growth. The data from these carefully
done animal studies document novel eﬀects of statins on
left ventricular hypertrophy and open a potential new
therapeutic strategy for patients with cardiac hypertrophy.
Clinical trials to test statins beneﬁt in patients at risk with
left ventricular hypertrophy are in progress.
Another potential therapeutic target for the treatment
of hypertension and to facilitate the regression of left
ventricular hypertrophy is the renal sympathetic eﬀerent and
aﬀerent nerves, which lie within and immediately adjacentInternational Journal of Hypertension 7
to the wall of the renal arteries, and contribute to the
maintenance of hypertension [73]. Because the causative
factors of hypertension change over time, the denervation
of both eﬀerent and aﬀerent renal sympathetic nerves
should result in long-term attenuation of hypertension.
The importance of the renal nerves in the hypertensive
patient has now been deﬁned with the novel development
of percutaneous, minimally invasive renal denervation from
within the renal artery using radiofrequency energy as a
therapeutic strategy. Studies, thus far, show that catheter-
based renal denervation in patients with resistant essential
hypertension lowers systolic blood pressure 27mmHg by
12 months with the estimated glomerular ﬁltration rate
remaining stable [74] .T h ed e c r e a s ei na r t e r i a lp r e s s u r ea f t e r
renal denervation is associated with decreased peripheral
sympathetic nervous system activity suggesting that the
kidney is a source of signiﬁcant sympathetic outﬂow via
aﬀerent renal nerve activity. Patients whose hypertension
is mediated by important sympathetic nervous system-
renal factors represent a new potential therapeutic target
for, not only treatment of resistant hypertension, but also
left ventricular hypertrophy. Since increased central sympa-
thetic outﬂow is believed to contribute to left ventricular
hypertrophy, the reduction of central sympathetic outﬂow
following renal denervation may facilitate the regression of
left ventricular hypertrophy. If proved true in prospective
studies, this therapy may have unique value in reversing
left ventricular hypertrophy. This concept is supported, thus
far, in a recent case report of a 59-year-old patient with
longstanding essential hypertension resistant to multidrug
treatment [75]. After renal denervation, a gradual reduction
of systolic blood pressure of 30mmHg over 12 months was
accompanied by an eight percent decrease in left ventricular
mass as measured by cardiovascular magnetic resonance.
8. Conclusions
Hypertensive left ventricular hypertrophy is a pathologic
response resulting in diastolic dysfunction and decreased
coronary ﬂow reserve. Left ventricular hypertrophy increases
the risk for atrial ﬁbrillation, diastolic heart failure, systolic
heart failure, and sudden death in patients with hyper-
tension. An echocardiogram and cardiovascular magnetic
resonance are useful tools to access left ventricular mass.
Controlling arterial pressure, sodium restriction, and weight
loss independently facilitate the regression of left ventricular
hypertrophy. Angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers followed by calcium channel
antagonists most rapidly facilitate the regression of left
ventricular hypertrophy. Increasing evidence indicates that
aldosterone receptor blockers are eﬀective in facilitating the
regression of left ventricular hypertrophy. Chlorthalidone
appears to be the most eﬀective thiazide-type diuretic
for treatment of hypertension. Carvedilol appears to be
the beta-blocker of choice in patients with hypertensive
left ventricular hypertrophy. Future novel approaches to
the treatment of left ventricular hypertrophy in patients
with hypertension are to facilitate regression with statins
and to attenuate the hypertension using cather-based renal
sympathetic denervation.
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